Probably would have been the intention post-approval regardless, seems fairly common for Aussie bio/pharma companies. We’re not even at that stage yet though, more likely end up selling this to a US player by the end of the year
Opthea (OPT) - The BREAKTRHOUGH in Vision Treatment IMMINENT, page-18
Add to My Watchlist
What is My Watchlist?